Implications of the ACCORD Lipid study: Perspective from the Residual Risk Reduction Initiative (R3i)

Current Medical Research and Opinion

Volumn 26, Issue 8, 2010, Pages 1793-1797

  Fruchart, J C ^a   Sacks, F M ^b   Hermans, M P ^c  

^a R3i Foundation at GTN   (France)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

ACCORD trial; Dyslipidaemia; High density lipoprotein cholesterol; Residual cardiovascular risk; Triglycerides; Type 2 diabetes

Indexed keywords

BEZAFIBRATE; CREATININE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROGENIC DYSLIPIDAEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; LIPIDS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 77954734498     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.489341     Document Type: Note

References (35)

1. Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117:1945-54
2. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
3. Juutilainen A, Pyorala K, Lehto S, et al. Type 2 diabetes as a 'coronary heart disease equivalent'. An 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901-7
4. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl 1):S12-54. [Updated 2009:Executive Summary: Standards of Medical Care in Diabetes-2009. Diabetes Care 2009;32(Suppl 1):S6-12]
5. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-61
6. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Executive summary. Eur Heart J 2007; 28:2375-414
7. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136
8. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidaemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009;25:567-79
9. Shepherd J, Barter P, Carmena R, et al.; for the Treating to New Targets Investigators. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6
10. Barter PJ, Gotto AM, LaRosa JC, et al.; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
11. Miller M, Cannon CP, Murphy SA, et al.; PROVE-IT TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30
12. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008;5:319-35
13. Assmann G, Schulte H, Cullen P. Non-LDL-related dyslipidemia and coronary risk, a case-control study. Diabetes Vasc Dis Research (in press)
14. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
15. Cushman WC, Grimm RH, Cutler JA, for the ACCORD study group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol 2007; 99(Suppl):44-55i
16. Ginsberg HN, Bonds D, Lovato LC, et al.; for the ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(Suppl 12A):56-67i
17. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45
18. Robins SJ, Collins D, Wittes JT, et al.; for the VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA 2001;285:1585-91
19. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
20. Scott R, O'Brien R, Fulcher G, et al. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 2009;32:493-8
21. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med 2010: published online 14 March 2010, DOI:10.1056/NEJMoa1001282
22. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60
23. Tenkanen L, Mantarri M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 1995;92:1779-85
24. Farnier M, Salko T, Isaacsohn JL, et al. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin\+ fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003;92:794-7
25. Brookes ST, Whitely E, Egger M, et al. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004;57:229-36
26. Paramsothy P, Knopp R, Bertoni AG, et al. Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis (MESA). Metabolism 2009;58:212-19
27. Keech A, Simes RJ, Barter P, et al.; The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
28. Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485-93
29. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97
30. Rajamani K, Colman PG, Li LP, et al.; FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780-8
31. Adiels M, Olofsson S-O, Taskinen M-R, et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-36
32. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010: published on-line 11 May 2010, DOI:10.1016/S0140-6736(10)60656-3
33. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45
34. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipopro-tein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18
35. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3, updated 2009/20/05. Available at: www.OpenEpi.com [accessed 25 March 2010]